



March 25, 2026

To Whom It May Concern,

Company Name: Kubota Pharmaceutical Holdings Co., Ltd.

Title and Name of Representative: Ryo Kubota

Director, Chairman, President, and CEO

(TSE Growth: Code 4596)

Contact: Public Relations & Investor Relations

(TEL : 03-6550-8928 (main))

Notice Regarding Conclusion of Discussions and Termination of the Sales Agreement for “Kubota Glass[®]”
with Sakata Pharmaceutical Company

Kubota Pharmaceutical Holdings Co., Ltd. (Headquarters: Minato-ku, Tokyo; Representative: Ryo Kubota; hereinafter referred to as the “Company”) hereby announces that, with mutual agreement between the Company and Sakata Pharmaceutical Company (Headquarters: Hannan City, Osaka; Representative Director and President: Miyuki Sakata; hereinafter referred to as “Sakata Pharmaceutical”), discussions regarding the sales agreement for “Kubota Glass[®]” entered into on March 13, 2025 were concluded, and the sales agreement was terminated as of March 25, 2026, as described below.

Records

1. Reason for the conclusion of discussions

The Company and Sakata Pharmaceutical had continued discussions toward the performance of the sales agreement. However, while the prospect of receiving a concrete purchase order from Sakata Pharmaceutical remained uncertain, the Company entered into distributorship agreements and sales agreements with four companies in mainland China and one company in Taiwan in September and November 2025, and also resumed direct sales through the Chinese e-commerce platform Taobao, while promoting sales activities through both distributors and direct sales channels.

In light of these circumstances, the Company determined that, in order to further expand “Kubota Glass[®],” it was necessary to terminate its relationship with Sakata Pharmaceutical and focus on new sales channels. Accordingly, by mutual agreement of the parties, the Company and Sakata Pharmaceutical agreed to terminate the sales agreement and conclude all discussions and business relationships.

2. Overview of the sales agreement subject to termination

Under the sales agreement entered into on March 13, 2025, Sakata Pharmaceutical agreed to purchase 600 units of “Kubota Glass[®]” from the Company by August 2025 (approximately JPY 260 million).



It should be noted that the Letter of Intent (LOI), which served as a premise for the sales agreement, had already been terminated as of September 3, 2025 (as previously disclosed on August 20, 2025).

3. Manufacturing status related to the sales agreement and accounting treatment of inventory

Based on the assumption that this sales agreement would be performed, the Company placed orders for the necessary long-lead-time components and currently holds them as inventory of parts prior to assembly. With respect to such inventory, the Company conducted the necessary valuation in the fiscal year ended December 31, 2025 (the previous fiscal year) and has already recorded a valuation loss.

4. Overview of the Party

(1) Name	Sakata Pharmaceutical Company
(2) Location	Osaka-fu Hannan-shi Ozaki-cho 1-chome-44-1, Osaka, Japan
(3) Representative's Position and Name	President & CEO, Miyuki Sakata
(4) History	Inter Techno Co., Ltd. was established on July 29, 2024 for the purpose of strengthening collaboration with the Hainan Free Trade Port in China. On November 19, 2024, it established its wholly owned subsidiary, Sakata Pharmaceutical (Hainan) Co., Ltd. In January 2025, it officially joined the China-Japan Industry and Education Integration Alliance. In February 2025, it entered into an agreement with Himawari-kai Medical Corporation to jointly implement a regenerative medicine project in China.
(5) Business Description	<ol style="list-style-type: none"> 1. Manufacturing, sales, and import/export of pharmaceuticals and quasi-drugs 2. Manufacturing, sales, and import/export of health foods and supplements 3. Sales and import/export of cosmetic containers and packaging 4. Planning, design, sales, and import/export of cosmetics 5. General merchandise sales and trading business 6. Various consulting services 7. Agency sales of medical devices and health & beauty equipment 8. Agency sales of cosmetic raw materials 9. E-commerce sales for domestic and international markets 10. Introduction of medical institutions and medical interpretation services for foreign patients seeking treatment in Japan
(6) Capital	Sakata Pharmaceutical Company: ¥1,000,000
	Sakata Pharmaceutical (Hainan) Co., Ltd.: ¥20,480,000
	Intertechno Co., Ltd.: ¥60,000,000
(7) Establishment Date	July 29, 2024



(8) Relationship with the Company	Capital Relationship	N/A
	Personnel Relationship	N/A
	Business Relationship	N/A
	Status as a Related Party	Sakata Pharmaceutical is not considered a related party, and its affiliates and related companies are not considered related parties to our Company.

5. Date of termination

March 25, 2026

6. Future outlook

The Company does not provide earnings forecasts and will continue to carefully evaluate the impact of this matter on its financial results.

end